Phase 1 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with primary Parkinson's disease, confirmed using recognised international or Chinese diagnostic guidelines
- People aged between 40 and 65 years old (inclusive) at the time of screening, of any sex
- People whose Parkinson's disease was diagnosed 5 years ago or less
- People whose Parkinson's symptoms, when not on medication, are at a mild stage (Hoehn & Yahr stage 2 or below)
Who may not be able to join:
- People whose condition has been identified as an atypical or secondary form of parkinsonism, such as a Parkinson's-plus syndrome, a hereditary form, or parkinsonism caused by medication
- People who have a medical reason why surgery would not be safe for them, or who have previously had a brain procedure such as deep brain stimulation, pallidotomy, or similar surgery
- People whose prior brain scans have shown structural abnormalities, blood vessel problems, brain tumours, bleeding risk, brain injury, or other significant findings
- People who score below 24 on a standard memory and thinking assessment (confirm with trial site)
- People who score 16 or above on a standard depression screening questionnaire (confirm with trial site)
- People whose liver or kidney function test results are significantly above the normal range
- People who have a blood clotting disorder or who are currently taking blood-thinning medication
- People who test positive for Hepatitis B, Hepatitis C, HIV, or syphilis during screening
- People who are currently receiving antiviral treatment for Hepatitis B or C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 64370045
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PDR-001 treatment-related adverse events as assessed by CTCAE v5.0; Titer levels of capsid neutralizing antibodies and binding antibodies against recombinant adeno-associated virus (rAAV) in serum; Titer of rAAV vectors in whole blood
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.